This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Ten primary studies were considered.
Methods of combining primary studies
Investigation of differences between primary studies
Not carried out.
Results of the review
The proportion of women aged 35 years and older was 9.6%. The patient's a priori risk for foetal DS was based on both maternal age and gestational age.
The first-and second-trimester foetal DS loss rates before term were estimated to be 30% (first-trimester) and 21% (second-trimester), respectively.
For first-trimester screening, the sensitivity was 91% and the rate of screen positives was 5%. For second-trimester screening, the sensitivity was 70% and the rate of screen positives was 7.5%. However, the sensitivity of secondtrimester screening was 57% in women without ultrasound dating. Also, in the second-trimester screening of women who had never undergone ultrasound screening, the initial and final screen positive rates were 14% (initial) and 9.9% (final), respectively. These revised figures for women receiving second-trimester screening without prior ultrasound were used in a sensitivity analysis of ultrasound usage rates (0% and 50%).
Methods used to derive estimates of effectiveness
The authors made some assumptions, owing to the lack of some effectiveness data.
Estimates of effectiveness and key assumptions
A singleton, viable intrauterine pregnancy was assumed at the time of screening for all 10,000 women considered in the study. All patients underwent routine first-trimester ultrasound screening to confirm foetal number, foetal viability, and gestational age. All patients who underwent second-trimester screening would have undergone a limited first-trimester
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Measure of benefits used in the economic analysis
Several output measures were calculated to assess the benefits of the two screening strategies:
the expected number of DS cases in the whole cohort, the number of patients with positive screen results, the rate of DS cases detected, the yield of screening, the number of DS cases missed, and the number of DS cases live-born.
Best and worst cases were considered for second-trimester screening.
Direct costs
Discounting was not relevant since the costs were incurred during a short time. The unit costs were presented separately from the quantities of resources used for some items. The health services included in the economic evaluation were screening tests and live-born DS costs. The screening tests covered ultrasound, serum screening and amniocentesis/chorionic villi sampling, but not tests for other foetal chromosomal and/or structural anomalies. Liveborn DS costs included all medical and non-medical services related to DS management. The cost/resource boundary of the health care payer was adopted in the analysis. Resource use data were estimated from the literature. The costs were derived from insurance reimbursement rates and published studies. The price year was 2000.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs were not considered.
Currency

US dollars ($).
Sensitivity analysis
A univariate sensitivity analysis was conducted. This assessed the impact of variations in ultrasound rate and other basecase assumptions on the estimated costs and efficacy rates. No justification for the ranges used was provided.
Estimated benefits used in the economic analysis
The expected number of DS cases in the whole cohort was 21 at the time of first-trimester screening.
The number of patients with positive screen results was 500 for first-trimester screening and 500 with best-case secondtrimester screening (750 with worst-case second-trimester screening).
The rate of DS cases detected was 72.9% for first-trimester screening and 62.4% with best-case second-trimester screening (55.8% with worst-case second-trimester screening).
